AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, th...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: O’Hare, Thomas, Shakespeare, William C., Zhu, Xiaotian, Eide, Christopher A., Rivera, Victor M., Wang, Frank, Adrian, Lauren T., Zhou, Tianjun, Huang, Wei-Sheng, Xu, Qihong, Metcalf, Chester A., Tyner, Jeffrey W., Loriaux, Marc M., Corbin, Amie S., Wardwell, Scott, Ning, Yaoyu, Keats, Jeffrey A., Wang, Yihan, Sundaramoorthi, Raji, Thomas, Mathew, Zhou, Dong, Snodgrass, Joseph, Commodore, Lois, Sawyer, Tomi K., Dalgarno, David C., Deininger, Michael W.N., Druker, Brian J., Clackson, Tim
Format: Artigo
Sprog:Inglês
Udgivet: 2009
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2804470/
https://ncbi.nlm.nih.gov/pubmed/19878872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2009.09.028
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker